Overview

Lysine (K)-specific demethylase 2B (KDM2B) is a gene that encodes a protein that belongs to the F-box protein family. The protein is a component of the ubiquitin protein ligase complex that functions in phosphorylation-dependent ubiquitination. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.

KDM2B is altered in 0.16% of all cancers with colon adenocarcinoma, lung adenocarcinoma, myelodysplastic syndromes, pancreatic adenocarcinoma, and cancer, NOS having the greatest prevalence of alterations [3].

The most common alterations in KDM2B are KDM2B Mutation (3.00%), KDM2B K930E (0.42%), KDM2B D168H (0.17%), KDM2B L466P (0.17%), and KDM2B A217T (0.08%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.